CD8+ TILs in melanoma and SCC share important common features, including the coordinated expression of immune checkpoint receptors and the development of resistance to immunotherapy (29, 31, 32), yet the mechanisms underlying TIL dysfunction in these tumors remain elusive. The gene discussed is CD8A; the disease is melanoma.